Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS.

Fox EJ, Lublin FD, Wolinsky JS, Cohen JA, Williams IM, Meng X, Ziehn M, Kolodny S, Cree BAC.

Neurol Neuroimmunol Neuroinflamm. 2019 Sep 11;6(6). pii: e614. doi: 10.1212/NXI.0000000000000614. Print 2019 Nov.

2.

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators.

Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.

PMID:
31495497
3.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators.

Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.

PMID:
31492652
4.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators.

Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.

PMID:
31492651
5.

Telomere Length Is Associated with Disability Progression in Multiple Sclerosis.

Krysko KM, Henry RG, Cree BAC, Lin J; University of California, San Francisco MS-EPIC Team, Caillier S, Santaniello A, Zhao C, Gomez R, Bevan C, Smith DL, Stern W, Kirkish G, Hauser SL, Oksenberg JR, Graves JS.

Ann Neurol. 2019 Nov;86(5):671-682. doi: 10.1002/ana.25592. Epub 2019 Oct 2.

PMID:
31486104
6.

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.

Cantó E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, Tomic D, Santaniello A, Häring DA, Hollenbach J, Henry RG, Cree BAC, Kappos L, Leppert D, Hauser SL, Benkert P, Oksenberg JR, Kuhle J.

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2137. [Epub ahead of print]

PMID:
31403661
7.

Reply to "Silent Progression or Bout Onset Progressive Multiple Sclerosis?"

Cree BAC, Hauser SL.

Ann Neurol. 2019 Sep;86(3):472-473. doi: 10.1002/ana.25536. Epub 2019 Jul 12. No abstract available.

PMID:
31251816
8.

Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm.

Cree BAC, Mares J, Hartung HP.

Curr Opin Neurol. 2019 Jun;32(3):365-377. doi: 10.1097/WCO.0000000000000700.

PMID:
30985372
9.

Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis.

Block VJ, Bove R, Zhao C, Garcha P, Graves J, Romeo AR, Green AJ, Allen DD, Hollenbach JA, Olgin JE, Marcus GM, Pletcher MJ, Cree BAC, Gelfand JM.

JAMA Netw Open. 2019 Mar 1;2(3):e190570. doi: 10.1001/jamanetworkopen.2019.0570.

10.

Silent progression in disease activity-free relapsing multiple sclerosis.

University of California, San Francisco MS-EPIC Team, Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS, Gelfand JM, Graves J, Green AJ, Wilson MR, Zamvil SS, Zhao C, Gomez R, Ragan NR, Rush GQ, Barba P, Santaniello A, Baranzini SE, Oksenberg JR, Henry RG, Hauser SL.

Ann Neurol. 2019 May;85(5):653-666. doi: 10.1002/ana.25463. Epub 2019 Mar 30.

11.

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser SL.

J Neurol. 2019 May;266(5):1182-1193. doi: 10.1007/s00415-019-09248-6. Epub 2019 Feb 28.

12.

Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis.

Greenfield AL, Dandekar R, Ramesh A, Eggers EL, Wu H, Laurent S, Harkin W, Pierson NS, Weber MS, Henry RG, Bischof A, Cree BA, Hauser SL, Wilson MR, von Büdingen HC.

JCI Insight. 2019 Mar 21;4(6). pii: 126599. doi: 10.1172/jci.insight.126599. eCollection 2019 Mar 21.

13.

pRNFL as a marker of disability worsening in the medium/long term in patients with MS.

Cordano C, Nourbakhsh B, Devereux M, Damotte V, Bennett D, Hauser SL, Cree BAC, Gelfand JM, Green AJ.

Neurol Neuroimmunol Neuroinflamm. 2018 Dec 21;6(2):e533. doi: 10.1212/NXI.0000000000000533. eCollection 2019 Mar. No abstract available.

14.

Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.

Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M.

Neurology. 2019 Jan 15;92(3):151. doi: 10.1212/WNL.0000000000006774. No abstract available.

PMID:
30643034
15.

The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod.

Cohen JA, Bar-Or A, Cree BAC, Mao-Draayer Y, Han MH, Singer B, Jannu A, Kolodny S, Meng X, Winger RC.

Mult Scler J Exp Transl Clin. 2019 Jan 2;5(1):2055217318819245. doi: 10.1177/2055217318819245. eCollection 2019 Jan-Mar.

16.

Disease-modifying therapies alter gut microbial composition in MS.

Katz Sand I, Zhu Y, Ntranos A, Clemente JC, Cekanaviciute E, Brandstadter R, Crabtree-Hartman E, Singh S, Bencosme Y, Debelius J, Knight R, Cree BAC, Baranzini SE, Casaccia P.

Neurol Neuroimmunol Neuroinflamm. 2018 Oct 26;6(1):e517. doi: 10.1212/NXI.0000000000000517. eCollection 2019 Jan.

17.

Rituximab in neurological disease: principles, evidence and practice.

Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, Robertson NP, Cree BAC, Jacob A.

Pract Neurol. 2019 Feb;19(1):5-20. doi: 10.1136/practneurol-2018-001899. Epub 2018 Nov 29. Review.

PMID:
30498056
18.

Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria.

Cekanaviciute E, Pröbstel AK, Thomann A, Runia TF, Casaccia P, Katz Sand I, Crabtree E, Singh S, Morrissey J, Barba P, Gomez R, Knight R, Mazmanian S, Graves J, Cree BAC, Zamvil SS, Baranzini SE.

mSystems. 2018 Nov 6;3(6). pii: e00083-18. doi: 10.1128/mSystems.00083-18. eCollection 2018 Nov-Dec.

19.

Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.

Bove R, Bevan C, Crabtree E, Zhao C, Gomez R, Garcha P, Morrissey J, Dierkhising J, Green AJ, Hauser SL, Cree BA, Wallin MT, Gelfand JM.

Mult Scler. 2019 Oct;25(11):1526-1534. doi: 10.1177/1352458518793527. Epub 2018 Aug 24.

PMID:
30141729
20.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2019 Aug;25(9):1255-1262. doi: 10.1177/1352458518789884. Epub 2018 Jul 25.

21.

Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.

Cascione M, Tenenbaum N, Wendt J, Meng X, Schofield L, Cree BAC; PREFERMS investigators.

Mult Scler Relat Disord. 2018 Oct;25:50-56. doi: 10.1016/j.msard.2018.07.014. Epub 2018 Jul 11.

22.

Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BAC, Oksenberg JR, Hauser SL, Baranzini SE.

Ann Neurol. 2018 Jul;84(1):51-63. doi: 10.1002/ana.25263. Epub 2018 Jul 3.

23.

Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial.

Cree BAC, Arnold DL, Cascione M, Fox EJ, Williams IM, Meng X, Schofield L, Tenenbaum N.

Ther Adv Neurol Disord. 2018 May 20;11:1756286418774338. doi: 10.1177/1756286418774338. eCollection 2018.

24.

Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach?

Cree BAC.

J Neuroophthalmol. 2018 Jun;38(2):258-262. doi: 10.1097/WNO.0000000000000640. Review. No abstract available.

PMID:
29750736
25.

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):789-800. doi: 10.1212/WNL.0000000000005345. Review. Erratum in: Neurology. 2019 Oct 22;93(17):769.

PMID:
29686117
26.

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):777-788. doi: 10.1212/WNL.0000000000005347. Erratum in: Neurology. 2019 Jan 8;92(2):112.

PMID:
29686116
27.

Progressive multifocal leukoencephalopathy after fingolimod treatment.

Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M.

Neurology. 2018 May 15;90(20):e1815-e1821. doi: 10.1212/WNL.0000000000005529. Epub 2018 Apr 18.

28.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
29.

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.

Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, Green AJ, Hauser SL, Bove R.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 19;5(3):e453. doi: 10.1212/NXI.0000000000000453. eCollection 2018 May.

30.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

31.

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.

Cree BA.

Mult Scler. 2018 Aug;24(9):1161-1162. doi: 10.1177/1352458518760717. Epub 2018 Feb 22. No abstract available.

PMID:
29468947
32.

Harnessing electronic medical records to advance research on multiple sclerosis.

Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA.

Mult Scler. 2019 Mar;25(3):408-418. doi: 10.1177/1352458517747407. Epub 2018 Jan 9.

PMID:
29310490
33.

The Gut Microbiome in Neuromyelitis Optica.

Zamvil SS, Spencer CM, Baranzini SE, Cree BAC.

Neurotherapeutics. 2018 Jan;15(1):92-101. doi: 10.1007/s13311-017-0594-z. Review.

34.

Ovarian aging is associated with gray matter volume and disability in women with MS.

Graves JS, Henry RG, Cree BAC, Lambert-Messerlian G, Greenblatt RM, Waubant E, Cedars MI, Zhu A; University of California, San Francisco MS-EPIC Team,, Bacchetti P, Hauser SL, Oksenberg JR.

Neurology. 2018 Jan 16;90(3):e254-e260. doi: 10.1212/WNL.0000000000004843. Epub 2017 Dec 22.

35.

Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury.

Cree BAC, Niu J, Hoi KK, Zhao C, Caganap SD, Henry RG, Dao DQ, Zollinger DR, Mei F, Shen YA, Franklin RJM, Ullian EM, Xiao L, Chan JR, Fancy SPJ.

Brain. 2018 Jan 1;141(1):85-98. doi: 10.1093/brain/awx312.

36.

Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients.

Eggers EL, Michel BA, Wu H, Wang SZ, Bevan CJ, Abounasr A, Pierson NS, Bischof A, Kazer M, Leitner E, Greenfield AL, Demuth S, Wilson MR, Henry RG, Cree BA, Hauser SL, von Büdingen HC.

JCI Insight. 2017 Nov 16;2(22). pii: 92724. doi: 10.1172/jci.insight.92724. eCollection 2017 Nov 16.

37.

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.

Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F.

Mult Scler J Exp Transl Clin. 2017 Oct 9;3(4):2055217317732802. doi: 10.1177/2055217317732802. eCollection 2017 Oct-Dec.

38.

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR.

Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2. Epub 2017 Oct 10.

39.

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC.

Neurology. 2017 Oct 10;89(15):1584-1593. doi: 10.1212/WNL.0000000000004485. Epub 2017 Sep 15.

40.

Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.

Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11. Erratum in: Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8943.

41.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2018 Oct;24(11):1485-1498. doi: 10.1177/1352458517726657. Epub 2017 Aug 29.

42.

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.

Gelfand JM, Cree BAC, Hauser SL.

Neurotherapeutics. 2017 Oct;14(4):835-841. doi: 10.1007/s13311-017-0557-4. Review.

43.

Acute liver injury in a Glatopa-treated patient with MS.

Sabatino JJ Jr, Mehta NJ, Kakar S, Zamvil SS, Cree BAC.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 5;4(4):e368. doi: 10.1212/NXI.0000000000000368. eCollection 2017 Jul. No abstract available.

44.

Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis.

Seraji-Bozorgzad N, Khan O, Cree BAC, Bao F, Caon C, Zak I, Razmjou S, Tselis A, Millis S, Bernitsas E.

J Neuroimaging. 2017 Sep;27(5):476-480. doi: 10.1111/jon.12435. Epub 2017 Mar 29.

PMID:
28371088
45.

Onset of secondary progressive MS after long-term rituximab therapy - a case report.

von Büdingen HC, Bischof A, Eggers EL, Wang S, Bevan CJ, Cree BA, Henry RG, Hauser SL.

Ann Clin Transl Neurol. 2016 Dec 20;4(1):46-52. doi: 10.1002/acn3.377. eCollection 2017 Jan.

46.

Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.

Block VJ, Lizée A, Crabtree-Hartman E, Bevan CJ, Graves JS, Bove R, Green AJ, Nourbakhsh B, Tremblay M, Gourraud PA, Ng MY, Pletcher MJ, Olgin JE, Marcus GM, Allen DD, Cree BA, Gelfand JM.

J Neurol. 2017 Feb;264(2):316-326. doi: 10.1007/s00415-016-8334-6. Epub 2016 Nov 28.

47.

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.

Varrin-Doyer M, Pekarek KL, Spencer CM, Bernard CC, Sobel RA, Cree BA, Schulze-Topphoff U, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 21;3(5):e272. eCollection 2016 Oct.

48.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

49.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

50.

Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens.

Cree BA, Spencer CM, Varrin-Doyer M, Baranzini SE, Zamvil SS.

Ann Neurol. 2016 Sep;80(3):443-7. doi: 10.1002/ana.24718. Epub 2016 Aug 4.

Supplemental Content

Support Center